This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MRE0094, MRE-0094
Description: Sonedenoson is an adenosine A2A receptor agonist that regulates the response of inflammatory cells and mediators and enhances the tissue proliferation phase of wound healing.
Deal Structure: In October 2010, Pfizer and King Pharmaceuticals announced that they have entered into a definitive merger agreement.
Additional information available to subscribers only: